Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $27.22M rose 122.3% year over year, ahead of the +91.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 104.8% from the prior quarter. Over 3 fiscal years it compounded at +45.8% a year.
Context
- Stock-based compensation amounted to 9.2% of revenue in FY2025, down 6.0 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +122.3% holds above the trailing-twelve-month pace of +91.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 41.72M USD
- Year-over-year change
- +50.0%
- 4-year CAGR
- +49.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.72M | +50.0% |
| FY2024 | 2024-12-31 | 27.82M | +40.3% |
| FY2023 | 2023-12-31 | 19.83M | +47.3% |
| FY2022 | 2022-12-31 | 13.46M | +59.2% |
| FY2021 | 2021-12-31 | 8.46M | — |
Stock-Based Compensation vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's LTM Sep 2026 stock-based compensation of $66.79M is the largest of the 6 companies compared; the peer median is $3.19M.
- Its year-over-year change of +91.9% is the highest of 4, against a peer median of -34.6%.
- Stock-based compensation amounts to 9.8% of revenue for TARS, versus a peer median of 9.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $66.79M | +91.9% | +45.8% | 9.8% | |
| LTM Jun 2026 | $43.55M | +10.4% | +7.3% | 9.4% | |
| LTM Mar 2026 | $11.78M | -34.6% | +16.2% | 4.4% | |
| LTM Mar 2026 | $3.19M | -47.9% | -12.7% | 8.6% | |
| LTM Jun 2024 | $2.13M | — | — | 32.5% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TARS) | $3.19M | -34.6% | +7.3% | 9.0% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.83M) | (62.09M) | (135.89M) | (115.55M) | (66.42M) |
| Depreciation & Amortization | 312K | 326K | 877K | 1.23M | 1.82M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.46M | 13.46M | 19.83M | 27.82M | 41.72M |
| Change in Working Capital | 1.37M | (951K) | 306K | 3.84M | 14.64M |
| Accounts Receivables | (73K) | (3.49M) | (14.13M) | (30.14M) | (39.05M) |
| Inventory | 0 | 3.49M | (3.11M) | (2.05M) | (1.75M) |
| Accounts Payables | 3.88M | 821K | 13.24M | 40.34M | 6.91M |
| Other Working Capital | (2.44M) | (1.77M) | 4.3M | (4.31M) | 48.53M |
| Other Non-Cash Items | 7.44M | 226K | (2.61M) | (360K) | (4.21M) |
| Operating Cash Flow | 3.75M | (49.03M) | (117.49M) | (83.03M) | (12.45M) |
| Capital Expenditures | (586K) | (506K) | (5.5M) | (1.57M) | (9.86M) |
| Acquisitions (Net) | 0 | 144.12M | 0 | 0 | 0 |
| Purchases of Investments | 0 | (149.44M) | (28.66M) | (265.63M) | (394.06M) |
| Sales of Investments | 0 | 5.32M | 174.77M | 73M | 361.8M |
| Other Investing Activities | 0 | (144.12M) | (4M) | (5M) | 0 |
| Investing Cash Flow | (586K) | (144.63M) | 140.6M | (199.2M) | (42.12M) |
| Debt Repayment | 0 | 19.13M | 10M | 39.6M | 0 |
| Common Stock Issued | 21K | 74.86M | 120.18M | 115.06M | 143.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 21K | 93.99M | 130.18M | 154.66M | 143.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.18M | (99.67M) | 153.29M | (127.57M) | 88.82M |
| Free Cash Flow | 3.16M | (49.54M) | (123M) | (84.59M) | (22.31M) |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.